While these results supported the results obtained in previous studies, the high variability between individual cohort pharmacokinetics, the exclusion of patients with comorbidities, the pooling of subjects from two separate studies that examined two separate cancer types with variable FAP expression, and the variability in dosing were assessed as complicating aspects of this experimental design and weakened the clinical impact of this report. The gene discussed is FAP; the disease is cancer.